Subscribe To
Aerami therapeutics announces presentation of phase 1 clinical trial data for lead program aer-901 at the 2023 european respiratory society (ers) international congress
DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathin...
September 12, 2023, 1:48 pm
Masimo's (masi) pvi favored by study for gdft in elderly patients
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fl...
August 22, 2023, 2:17 pm
Marpai collaborates with nuvoair to offer value-based cardiopulmonary care to self-funded employer health plans
Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer healt...
July 5, 2023, 12:29 pm
Bellerophon provides clinical program update and reports first quarter 2023 financial results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 202...
May 15, 2023, 8:50 pm
Aerami therapeutics to present pharmacokinetic data supporting aer-901 (inhaled imatinib) for pulmonary hypertension at the 2023 american thoracic society (ats) international conference
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing ...
May 11, 2023, 12:00 pm
Fluid therapy market showing tremendous growth globally by 2023-2028| research report by leading players
cardiopulmonary Wake (CPR), Congestive Heart Failure (CHF), Infusion, Hypertonic Saline, Other) that wi...
January 27, 2023, 12:14 pm